Philadelphia Chromosome: all 110 studies

Page 1 of 2. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)RecruitingNCT06785324Not applicable
• A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLRecruitingNCT06220487Phase 2
• Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingNCT06061094Phase 2
• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesRecruitingNCT05442515Phase 1/2
• Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young AdultsRecruitingNCT02617004
• A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young AdultsRecruitingNCT02611492Phase 3
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Active, not recruitingNCT05456191Phase 3Results posted
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingNCT04971226Phase 3Results posted
• Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTerminatedNCT03576547Phase 1/2Results posted
• Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT03518112Phase 2Results posted
• Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaTerminatedNCT02819804Phase 1Results posted
• Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02484430Phase 2Results posted
• Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaTerminatedNCT02420717Phase 2Results posted
• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedNCT02311998Phase 1/2Results posted
• A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT02272777Phase 3Results posted
• Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase InhibitorsTerminatedNCT02228382Phase 4Results posted
• S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01925131Phase 1Results posted
• A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.CompletedNCT01743989Phase 3Results posted
• A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01667133Phase 1/2Results posted
• Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT01445080Phase 1/2Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaTerminatedNCT01383447Phase 1/2Results posted
• Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT01274351Phase 2Results posted
• Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma ConcentrationsTerminatedNCT01131325Phase 4Results posted
• Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic PhaseCompletedNCT01061177Phase 4Results posted
• Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal ResponseCompletedNCT01043874Phase 4Results posted
• Rollover Study of BMS-354825 in Patients With CML and Ph+ALLCompletedNCT01030718Phase 1/2Results posted
• Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00982488Phase 2Results posted
• Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic StudyCompletedNCT00978731Phase 1Results posted
• Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)TerminatedNCT00860535Phase 1Results posted
• Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00844298Phase 2Results posted
• Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive LeukemiasCompletedNCT00811070Phase 2Results posted
• Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to ImatinibTerminatedNCT00644878Phase 2Results posted
• Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CMLCompletedNCT00574873Phase 3Results posted
• A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid LeukemiaCompletedNCT00482703Phase 1/2Results posted
• A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaCompletedNCT00481247Phase 3Results posted
• A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT00471497Phase 3Results posted
• Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.CompletedNCT00390793Phase 2Results posted
• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaCompletedNCT00333840Phase 3Results posted
• Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive LeukemiasCompletedNCT00261846Phase 2Results posted
• An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaCompletedNCT00171249Phase 2Results posted
• An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast CrisisCompletedNCT00171158Phase 2Results posted
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesCompletedNCT00109707Phase 1/2Results posted
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid LeukemiaCompletedNCT00103844Phase 2Results posted
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to ImatinibCompletedNCT00101660Phase 2Results posted
• Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic LeukemiaCompletedNCT00061945Phase 1/2Results posted
• Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 2
• Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 2
• Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in ScotlandCompletedNCT05363488
• Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaWithdrawnNCT04845035Phase 2
• Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
• MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaNo longer availableNCT04559555
• Precision Dosing of Tyrosine Kinase Inhibitors in CML PatientsCompletedNCT03885830
• Iclusig PMS in CML or Ph+ALL PatientsStatus unknownNCT03709017
• CALLS: CML and Ph+ALL Low Level Mutation Prevalence SurveyCompletedNCT03647215
• Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplantsStatus unknownNCT03624530Phase 2/3
• PETHEMA-BLIN-01/PET069014 (BLIN-01)TerminatedNCT03523429Phase 2
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute LeukemiaTerminatedNCT03519984Phase 1
• Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaActive, not recruitingNCT03512405Phase 1/2
• Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT03509896
• Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in EgyptCompletedNCT03454503
• Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic LeukemiaCompletedNCT03367299Phase 2
• Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaStatus unknownNCT03318770
• Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALLCompletedNCT03249870Phase 2
• The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous LeukaemiaStatus unknownNCT03241199Phase 2
• Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and PrednisoneWithdrawnNCT02815059Phase 1
• Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid LeukemiaTerminatedNCT02782403Phase 1
• Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or OlderWithdrawnNCT02647190Phase 1
• Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCompletedNCT02523976Phase 2
• A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLCompletedNCT02081378Phase 1
• Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic LeukemiaStatus unknownNCT01990807Phase 4
• TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaStatus unknownNCT01883219Phase 2
• Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedNCT01751425Phase 1
• Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)CompletedNCT01724879Phase 2
• Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous LeukemiaWithdrawnNCT01670084Phase 2
• Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKICompletedNCT01602952Phase 1/2
• Expanded Access Program of PonatinibApproved for marketingNCT01592136
• Compassionate Use PonatinibNo longer availableNCT01549548
• Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT01528085Phase 2
• Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsCompletedNCT01511289Phase 3
• A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaStatus unknownNCT01503502Phase 2
• CD19 CAR T Cells for B Cell Malignancies After Allogeneic TransplantCompletedNCT01475058Phase 1/2
• Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior TherapyCompletedNCT01456676Phase 1
• Bioequivalence And Food Effect Study Of Bosutinib In Healthy SubjectsCompletedNCT01374139Phase 1
• De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) PatientsStatus unknownNCT01361438Phase 2
• Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND OptimisationCompletedNCT01243489Phase 4
• Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)SuspendedNCT01222013Phase 2
• Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)Status unknownNCT01221376Phase 2
• Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)CompletedNCT01220648Phase 1
• Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic LeukemiaCompletedNCT01132573Phase 1
• Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.TerminatedNCT01066468Phase 1
• Allogeneic Stem Cell Transplantation in CML With Partial T Cell DepletionStatus unknownNCT00966810Phase 2/3
• Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic LeukemiaCompletedNCT00940524Phase 1
• Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00816283Phase 1
• A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic MalignanciesCompletedNCT00807677Phase 1
• Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL PositiveCompletedNCT00763763Phase 2
• Correlative Biomarker Study in Patients With Myeloproliferative DisordersCompletedNCT00665067
• Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
• LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia PositiveCompletedNCT00526305Phase 4

← Philadelphia Chromosome overview